Tags

Type your tag names separated by a space and hit enter

Clone-derived human AF-amniotic fluid stem cells are capable of skeletal myogenic differentiation in vitro and in vivo.
J Tissue Eng Regen Med. 2012 Aug; 6(8):598-613.JT

Abstract

Stem cell-based therapy may be the most promising method to cure skeletal muscle degenerative diseases such as Duchenne muscular dystrophy (DMD) and trauma in the future. Human amniotic fluid is enriched with early-stage stem cells from developing fetuses and these cells have cardiomyogenic potential both in vitro and in vivo. In the present study, we investigated the characteristics of human amniotic fluid-derived AF-type stem (HAF-AFS) cells by flow cytometry, immunofluorescence staining, reverse-transcription polymerase chain reaction, and osteogenic and adipogenic differentiation analysis. After confirming the stemness of HAF-AFS cells, we tested whether HAF-AFS cells could differentiate into skeletal myogenic cells in vitro and incorporate into regenerating skeletal muscle in vivo. By temporary exposure to the DNA demethylation agent 5-aza-2'-deoxycytidine (5-Aza dC) or co-cultured with C2C12 myoblasts, HAF-AFS cells differentiated into skeletal myogenic cells, expressing skeletal myogenic cell-specific markers such as Desmin, Troponin I (Tn I) and α-Actinin. Four weeks after transplantation into cardiotoxin-injured and X-ray-irradiated tibialis anterior (TA) muscles of NOD/SCID mice, HAF-AFS cells survived, differentiated into myogenic precursor cells and fused with host myofibres. The findings that HAF-AFS cells differentiate into myogenic cells in vitro and incorporate in skeletal muscle regeneration in vivo hold the promise of HAF-AFS cell-based therapy for skeletal muscle degenerative diseases.

Authors+Show Affiliations

Department of Urology, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22396316

Citation

Ma, Xiaorong, et al. "Clone-derived Human AF-amniotic Fluid Stem Cells Are Capable of Skeletal Myogenic Differentiation in Vitro and in Vivo." Journal of Tissue Engineering and Regenerative Medicine, vol. 6, no. 8, 2012, pp. 598-613.
Ma X, Zhang S, Zhou J, et al. Clone-derived human AF-amniotic fluid stem cells are capable of skeletal myogenic differentiation in vitro and in vivo. J Tissue Eng Regen Med. 2012;6(8):598-613.
Ma, X., Zhang, S., Zhou, J., Chen, B., Shang, Y., Gao, T., Wang, X., Xie, H., & Chen, F. (2012). Clone-derived human AF-amniotic fluid stem cells are capable of skeletal myogenic differentiation in vitro and in vivo. Journal of Tissue Engineering and Regenerative Medicine, 6(8), 598-613. https://doi.org/10.1002/term.462
Ma X, et al. Clone-derived Human AF-amniotic Fluid Stem Cells Are Capable of Skeletal Myogenic Differentiation in Vitro and in Vivo. J Tissue Eng Regen Med. 2012;6(8):598-613. PubMed PMID: 22396316.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clone-derived human AF-amniotic fluid stem cells are capable of skeletal myogenic differentiation in vitro and in vivo. AU - Ma,Xiaorong, AU - Zhang,Shengli, AU - Zhou,Junmei, AU - Chen,Baisong, AU - Shang,Yafeng, AU - Gao,Tongbing, AU - Wang,Xue, AU - Xie,Hua, AU - Chen,Fang, Y1 - 2012/03/07/ PY - 2010/10/28/received PY - 2011/05/02/revised PY - 2011/07/01/accepted PY - 2012/3/8/entrez PY - 2012/3/8/pubmed PY - 2013/3/23/medline SP - 598 EP - 613 JF - Journal of tissue engineering and regenerative medicine JO - J Tissue Eng Regen Med VL - 6 IS - 8 N2 - Stem cell-based therapy may be the most promising method to cure skeletal muscle degenerative diseases such as Duchenne muscular dystrophy (DMD) and trauma in the future. Human amniotic fluid is enriched with early-stage stem cells from developing fetuses and these cells have cardiomyogenic potential both in vitro and in vivo. In the present study, we investigated the characteristics of human amniotic fluid-derived AF-type stem (HAF-AFS) cells by flow cytometry, immunofluorescence staining, reverse-transcription polymerase chain reaction, and osteogenic and adipogenic differentiation analysis. After confirming the stemness of HAF-AFS cells, we tested whether HAF-AFS cells could differentiate into skeletal myogenic cells in vitro and incorporate into regenerating skeletal muscle in vivo. By temporary exposure to the DNA demethylation agent 5-aza-2'-deoxycytidine (5-Aza dC) or co-cultured with C2C12 myoblasts, HAF-AFS cells differentiated into skeletal myogenic cells, expressing skeletal myogenic cell-specific markers such as Desmin, Troponin I (Tn I) and α-Actinin. Four weeks after transplantation into cardiotoxin-injured and X-ray-irradiated tibialis anterior (TA) muscles of NOD/SCID mice, HAF-AFS cells survived, differentiated into myogenic precursor cells and fused with host myofibres. The findings that HAF-AFS cells differentiate into myogenic cells in vitro and incorporate in skeletal muscle regeneration in vivo hold the promise of HAF-AFS cell-based therapy for skeletal muscle degenerative diseases. SN - 1932-7005 UR - https://www.unboundmedicine.com/medline/citation/22396316/Clone_derived_human_AF_amniotic_fluid_stem_cells_are_capable_of_skeletal_myogenic_differentiation_in_vitro_and_in_vivo_ L2 - https://doi.org/10.1002/term.462 DB - PRIME DP - Unbound Medicine ER -